{"id":"aminopicoline","rwe":[],"tags":[{"label":"aminopicoline","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Nitric oxide synthase, inducible","category":"target"},{"label":"NOS2","category":"gene"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aminton","offLabel":[],"synonyms":["aminopicoline hydrochloride","2-amino-4-picoline","aminopicoline","2-amino-4-methylpyridine","aminton","ascensil"],"timeline":[],"brandName":"Aminton","ecosystem":[],"mechanism":{"target":"Nitric oxide synthase, inducible","targets":[{"gene":"NOS2","source":"DrugCentral","target":"Nitric oxide synthase, inducible","protein":"Nitric oxide synthase, inducible"}],"modality":"Small Molecule","drugClass":"aminopicoline","explanation":"Think of nitric oxide like a messenger in your body that helps blood vessels relax and widen. When inducible nitric oxide synthase is overactive, it can produce too much nitric oxide, leading to problems like inflammation and tissue damage. Aminton helps by blocking this enzyme, reducing the amount of nitric oxide produced and potentially alleviating these issues.","oneSentence":"Aminton works by inhibiting the production of nitric oxide through the inhibition of inducible nitric oxide synthase.","technicalDetail":"Aminton acts as a competitive inhibitor of inducible nitric oxide synthase, specifically targeting the heme domain and reducing the enzyme's activity, thereby decreasing the production of nitric oxide."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/172","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=aminopicoline","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:15.068854","biosimilars":[],"competitors":[{"drugName":"arginine","drugSlug":"arginine","fdaApproval":"1973-02-28","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"chlorzoxazone","drugSlug":"chlorzoxazone","fdaApproval":"1958-08-15","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"hydrocortisone","drugSlug":"hydrocortisone","fdaApproval":"1952-08-05","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"aminopicoline","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"arginine","brandName":"arginine","genericName":"arginine","approvalYear":"1973","relationship":"same-target"},{"drugId":"chlorzoxazone","brandName":"chlorzoxazone","genericName":"chlorzoxazone","approvalYear":"1958","relationship":"same-target"},{"drugId":"hydrocortisone","brandName":"hydrocortisone","genericName":"hydrocortisone","approvalYear":"1952","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"394N1Z644H","UMLSCUI":"C0045846","PDB_CHEM_ID":" BVF","PUBCHEM_CID":"1533","IUPHAR_LIGAND_ID":"5111","MESH_SUPPLEMENTAL_RECORD_UI":"C015672"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Aminopicoline, also known as Aminton, is a small molecule drug class targeting inducible nitric oxide synthase. It is currently owned by an unknown entity, but its original development is not specified. The exact commercial status, indications, and pharmacokinetic properties of Aminton are unknown. As a result, its use and safety considerations cannot be fully evaluated. Further research is needed to determine its potential as a therapeutic agent.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}